Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll joins Proactive’s Tylah Tully to discuss the completion of dosing all participants in its Phase 1b IV-infused psilocin Healthy Human Volunteer Study conducted at CMAX Clinical Research in Adelaide. This trial involved the administration of TRP-8803, a proprietary IV-infused psilocin formulation, to 11 participants across three cohorts over a period of up to 150 minutes. The study aimed to refine dosing and infusion rates to maintain precise blood levels of psilocin for optimal therapeutic effects. All participants were safely discharged following treatment and dosing follow-up. This Phase 1b trial provided key insights into the blood concentration limits of psilocin required to maintain an ideal therapeutic zone. The results will support future patent applications and underpin upcoming trials targeting binge eating disorder (BED) and fibromyalgia syndrome (FMS). Carroll highlighted the trial's significance in advancing the company’s proprietary IV-infusion technology, which may overcome challenges associated with oral dosing of psychedelics. A Safety Review Council is evaluating the trial data to determine if safety criteria was met. The company will provide further updates upon review completion. Successful Phase 2a trials with TRP-8802 (oral psilocybin) have de-risked upcoming TRP-8803 trials. #Proactiveinvestors #TryptamineTherapeutics #ASX #Psilocin #ClinicalTrial #Phase1b #IVInfusion #Psychedelics #TRP8803 #TRP8802 #BingeEatingDisorder #Fibromyalgia #ClinicalResearch #CMAX #Adelaide #TherapeuticGoodsAdministration #Pharmaceutical #MentalHealth #SafetyReview #PatentApplication #DrugDevelopment #PatientSafety #Therapeutics #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews